Bupivacaine inhibits a small conductance calcium-activated potassium type 2 channel (SK2) in HEK 293 cells

CURRENT STATUS: POSTED

Hongfei Chen  chhfei@126.com
The First Affiliated Hospital of Wenzhou Medical University
Corresponding Author
ORCiD: 0000-0002-9345-1737

Fangfang Xia
The First Affiliated Hospital of Wenzhou Medical University

Zhousheng Jin
The First Affiliated Hospital of Wenzhou Medical University

Yuting He
The First Affiliated Hospital of Wenzhou Medical University

Zhengjie Chen
The First Affiliated Hospital of Wenzhou Medical University

Shi Wang
The First Affiliated Hospital of Wenzhou Medical University

Xixi Chen
The First Affiliated Hospital of Wenzhou Medical University

Zhijian Fu
Shandong Provincial Hospital

DOI:
10.21203/rs.2.338/v1

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
Bupivacaine, SK2 channel, inhibition, cardiotoxicity, HEK 293
Abstract

**Background:** Bupivacaine blocks many ion channels in the heart muscle, which could cause severe cardiotoxicity. Small conductance calcium-activated potassium type 2 channels (SK2 channels) are widely distributed in the heart cells and are involved in relevant physiological functions. However, whether bupivacaine can inhibit SK2 channels is still unknown. This study investigated the effect of bupivacaine on SK2 channels.

**Methods:** The SK2 channel gene was transfected into human embryonic kidney 293 cells (HEK-293 cells) with Lipofectamine 2000. The whole-cell patch clamp technique was used to study the effect of bupivacaine on SK2 channels. The inhibitory effect of various concentrations of bupivacaine on SK2 currents exhibited a non-linear relation, and the half-maximal inhibitory concentration (IC50) value was determined.

**Results:** Bupivacaine inhibited the SK2 channels reversibly in a dose-dependent manner. The IC50 value of bupivacaine, ropivacaine and lidocaine on the SK2 current was 133.7, 189.3, and 885.8 µM, respectively. The degree of SK2 current inhibition by bupivacaine was dependent on the intracellular concentration of free calcium.

**Conclusions:** The results of this study suggested a new inhibitory effect of bupivacaine on SK2 channels. Future studies should be concerned with the effects of SK2 on bupivacaine cardiotoxicity.

**Keywords:** Bupivacaine, SK2 channel, inhibition, cardiotoxicity, HEK 293.

**Background**

Bupivacaine is one of the long-acting, lipophilic local anaesthetics (LAs) that is used for analgesia during the perioperative period due to its high analgesic efficacy and long-lasting effect. However, accidental delivery or excessive absorption of bupivacaine into the blood circulation may cause severe arrhythmias or even cardiac arrest[1-3]. The
mechanism of bupivacaine cardiotoxicity has not been fully elucidated. It is currently believed that bupivacaine could block sodium[4, 5] and calcium[6, 7] and potassium channels[8, 9] which may be involved in bupivacaine cardiotoxicity.

Calcium-activated potassium channels are calcium-dependent channels triggered by intracellular calcium[10]. In humans potassium channels can be divided into three categories: large conductance channels, intermediate conductance channels and small conductance channels. Small conductance calcium-activated potassium type 2 channel (SK2) is a type of small conductance potassium channel that is involved in hyperpolarization after the action potential. The SK2 channels are distributed in the atria[11], ventricles[11], atrioventricular nodes[12], and Purkinje cells[13], which play an important role in cardiac conduction. Due to the important role of the SK2 channel in the action potential, its dysfunction may lead to atrial or ventricular arrhythmias[3, 14]. So far, there have been no reports on the effect of bupivacaine on the SK2 channels. We hypothesised that bupivacaine could directly suppress SK2 currents. There has been no report on the effect of bupivacaine on the SK2 channels.

In this study, we transfected HEK 293 cells with SK2 channels. The patch clamp whole-cell technique was applied to demonstrate that clinical concentrations of bupivacaine could inhibit SK2 currents. Our aim was to demonstrate the capacity of bupivacaine to inhibit SK2 channels and the effect of calcium concentration on its blockade.

Methods

**Cell line culture and gene transfection**

Human embryonic kidney 293 cells (HEK293 cells) were all purchased from the institute of life sciences of Chinese Academy of Sciences (China). After being harvested by 0.25% trypsin, the cell lines were grown at 37 °C in a 5% CO2 and 95% air atmosphere and cultured in Dulbecco’s Minimal Essential Medium (DMEM) mixed with 10% fetal bovine...
serum (FBS), 75 μg/mL streptomycin and 75 U/mL penicillin. Before transfection, cells were added into plate with a density of about $2 \times 10^5 \text{ cells/cm}^2$. Transfection was performed when the confluency reached about 85%. The plasmids (pCDNA3/rSK Ca2) used in this study were obtained from OriGene (USA). We performed all the transfections with Lipofectamine 2000 (Invitrogen, USA) followed the manufacturer's instructions. As described previously, we established stable expression SK2 channel in the HEK293 cells (the cells were named SK2 cells)[15]. Before patch clamp experiment, SK2 cells were seeded about 24 hours in the glass cover.

**Drugs and Solutions**

Trypsin, FBS, penicillin and streptomycin and DMEM were all obtained from Gibco Invitrogen Corp.(USA); Bupivacaine, tropicacaine and lidocaine were purchased from Sigma-Aldrich (USA). The tyrode's solution was composed of the following, in mM: NaCl 137, KCl 5.4, MgCl2 1.8, HEPES 10, and glucose 10, pH was maintained at 7.4 with NaOH. The pipette solution was composed of the following, in mM: MgCl2 1.15, EGTA 1, HEPES 10, Potassium gluconate 144, and CaCl2 (0.25, 0.5 or 1.0), pH was maintained at 7.2 with KOH.

**Patch-clamp experiments**

All experiments were conducted with the patch clamp whole-cell technique[16]. The coverslip containing SK2 cells was placed into an inverted olympus microscope (IX70, Japan) on the cell chamber and perfused with the tyrode solution (the flow rate was about 1 ml/min).

The EPC-10 amplifier (HEKA, Germany) was applied for patch clamp whole-cell technique.

A glass electrode having an outer diameter of 1.2 mm was pulled out by the microelectrode puller (P-97, SUTTER, USA) to achieve a resistance of 1.5-3.0 MΩ after
adding the pipette solution. Under the microscope, SK2 cells with smooth cell membranes were picked up to record the currents. After giga-seal achievement, we give a negative pressure to break the membrane of SK2 cells. Voltage stimulation and data recording were performed by a Pulse 8.0 software (HEKA, Germany). All experiments were performed at a temperature of 26°C. The stimulation program of SK2 currents was as follows: holding potential was maintained at -80 mV, the step clamp voltage was given from -120 mV to +40 mV at a step of 10 mV with a 200 ms duration (Figure 1A). The ramp clamp voltage was stimulated from +40 mV to -120 mV with a 300 ms duration (Figure 1B). SK2 cells could produce stable currents at 0 mV; therefore, we used currents at 0 mV for comparisons in the following experiments.

**Statistical Analysis**

The SPSS software (version 19.0, Chicago, IL, USA) was used to analyse the data. The normality of data was tested using the Shapiro-Wilk test and the normally distributed data was expressed as the mean±standard deviation. Differences between the two groups were assessed by unpaired Student's t-test, and ANOVA was used for comparisons of multiple groups. The relationship between local anaesthetic concentration and its inhibitory effect on SK2 currents was fitted according to a non-linear model using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). A P value < 0.05 was considered to indicate statistical significance.

**Results**

**Characteristics of SK2 currents from SK2 cells**

Before the experiment, the whole-cell patch-clamp technique was used to determine the characteristics of SK2 currents. HEK 293 cells transfected with the SK2 gene (the transfected cells were named SK2 cells) could produce representative current tracings, but wild-type HEK293 cells could not (Figure 1A). The SK2 current could also be activated
according to the voltage ramp protocol in SK2 cells (Figure 1B). Figure 1C depicts the time course of the SK2 current before and after apamin. The currents were both obtained at 0 mV. Similar results were observed separately in 8 SK2 cells. SK2 cells could produce stable currents at 0 mV; therefore, we used currents at 0 mV for comparisons in the following experiments.

**Concentration response relationship of bupivacaine, ropivacaine and lidocaine on the inhibition of SK2 currents**

The effect of bupivacaine on SK2 currents was determined on the SK2 cells. As the concentration of bupivacaine increased, the SK2 currents decreased gradually in the SK2 cells (Figure 2A). The concentration response relationship of bupivacaine on the inhibition of SK2 current (at 0 mV) was fitted according to a non-linear model. The half-maximal inhibitory concentration (IC50) value for bupivacaine was 133.7 μmol/L (95% CI 87.33 - 204.6) (Figure 2B). The concentration response relationship of ropivacaine and lidocaine was also fitted according to the same model. The IC50 value for ropivacaine and lidocaine was 189.3 μmol/L (95% CI 153.7 - 233.2) and 885.8 μmol/L (95% CI 499.9 - 1570), respectively (Figure 2C and 2D).

**Inhibition of SK2 currents with LAs was reversible**

Next we explored whether the inhibitory effect of bupivacaine was reversible. In this part, the SK2 currents from SK2 cells were recorded exposing to 10, 100 and 1000 μM bupivacaine. It showed that SK2 currents measured at membrane potential of 0 mV were completely reversed to the baseline value after washout (P<0.05) (Figure 3).

**Modulation of the inhibitory effect of bupivacaine by the calcium concentration**

The opening probability of the SK2 channel is related to the intracellular calcium concentration. Here, we tested whether the inhibitory effect of bupivacaine on the SK2 current was affected by the calcium concentration. Figure 4A shows SK2 current traces
induced with intracellular free calcium concentrations of 0.25, 0.50 and 1.0 mM. The results showed that the SK2 currents were increased when the calcium concentration reached 1.0 mM (P < 0.05). Figure 4B shows that SK2 currents were inhibited by bupivacaine to different levels with exposure to different intrapipette concentrations of free calcium. The results showed that the inhibition of the SK2 current was the least at a calcium concentration of 1.0 mM (P < 0.05).

Discussion

The results showed that: (1) Bupivacaine could inhibit the SK2 channels reversibly in a dose-dependent way. (2) The IC50 values of bupivacaine, ropivacaine and lidocaine for inhibiting SK2 was 133.7, 189.3, and 885.8 µM, respectively. (3) The intracellular calcium concentration could affect the inhibition of bupivacaine on SK2 current.

After transfection with the SK2 channels, the SK2 cells produced stable SK2 currents, which could be inhibited by apamin. For this reason, the SK2 current is also called apamin-sensitive current[17]. Since the opening of the SK2 channel was mainly dependent on the calcium concentration, we recorded the SK2 current at a voltage of 0 mV. The intracellular free calcium concentration was controlled through the electrode solution, and the extracellular buffer did not contain free calcium. Therefore, the effect of bupivacaine on free calcium in SK2 cells was unlikely to affect its inhibition of the SK2 channel.

Bupivacaine cardiotoxicity results from the blockade of a wide range of myocardial ion channels, the most important being the sodium channel. In this study, we used the whole-cell patch-clamp technique to investigate the effects of LAs on SK2 currents, and measured the IC50 of bupivacaine, ropivacaine, and lidocaine. Bupivacaine ranked first in its potency of inhibition of SK2 currents, followed by ropivacaine and lidocaine. Interestingly, this order of potency is consistent with the order of LA cardiotoxicity. In the past, Pedro Martín[18] had studied the inhibitory effect of bupivacaine on large
conductance calcium-activated potassium channels in human umbilical artery smooth muscle cells. In his study, clinical concentrations of bupivacaine could block large conductance calcium-activated potassium channels. Additionally, Sbarbaro et al. [19] found that lidocaine could also block SK2 currents on nerve cells. However, lidocaine induced SK2 current blockade only when it exceeded clinical concentrations. It has been suggested that the blockade of SK2 channels by lidocaine was unlikely to cause clinical effects. However, our study found that the SK2 channels were very sensitive to bupivacaine and ropivacaine. The specific mechanism of this inhibition is still unclear. Since the inhibitory effect of bupivacaine on the SK2 channel could affect different physiological functions, this inhibitory effect of bupivacaine might be taken into account in bupivacaine cardiotoxicity.

We also found that the intracellular calcium concentration could affect the inhibitory effect of bupivacaine on SK2 currents. The SK2 channel proteins are coupled with calmodulin, and calcium binding to calmodulin would affect the conformation and function of the SK2 channels[20]. Since studies have shown that bupivacaine might alter intracellular calcium concentrations, bupivacaine is expected to indirectly regulate the SK2 channel. To eliminate the effects of this process, this study controlled the intracellular calcium concentration in the pipette solution. According to the result of the present study, this concentration-dependent inhibition of SK2 currents suggests that concentration of intracellular free calcium may contribute to the cardiotoxicity of bupivacaine.

Since bupivacaine could inhibit several ion currents in the heart (e.g., sodium channels, L-calcium channels and potassium channels), this study adds SK2 channels to the list of ion channels affected by bupivacaine. SK2 channels could cause arrhythmia depending on their expression levels in cardiomyocytes[21, 22]. SK2 channels could cause arrhythmia...
when they are expressed too much or too little in cardiomyocytes [23]. SK2 channels also participate in the mitochondrial function [24-27]. Therefore, the effects of SK2 channels on the action potential and mitochondrial function suggest that the blockade of SK2 channels might be involved in the cardiotoxicity of bupivacaine. More experiments are needed to demonstrate this hypothesis.

**Limitations**

Under normal circumstances, the SK2 channel proteins are coupled with calmodulin, and calcium binding to calmodulin would affect the conformation and function of the SK2 channels [20]. However, because only the SK2 channels were transfected into HEK 293 cells in our study, this effect of calcium could not be observed.

**Conclusions**

The results of this study suggest a new inhibitory effect of bupivacaine on SK2 channels. Future studies should be concerned with the effects of SK2 on bupivacaine cardiotoxicity.

**Abbreviations**

SK2 channel: small conductance calcium-activated potassium type 2 channel; 
HEK-293 cell: human embryonic kidney 293 cell; 
Bupi: bupivacaine; 
IC50: half-maximal inhibitory concentration. 
Con: control;

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Funding**

This work was supported by the Natural Science Foundation of Zhejiang Province, China.
[grant numbers LQ18H090006] and Wenzhou Municipal Scientific and Technological Program Projects [grant number Y20170042].

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare no conflicts of interest.

Author contributions
1. H.C. Contribution: Design and conduct the study, analyze the data, and write the manuscript.
2. F.X. Contribution: Conduct the study and study data collection.
3. Z.J. Contribution: Conduct the study and write the manuscript.
4. Y.H. Contribution: study data collection.
5. J.C. Contribution: study data collection.
6. S.W. Contribution: study data collection.
7. X.C. Contribution: study data collection.
8. Z.F. Contribution: Design and conduct the study, analyze the data, and write the manuscript.

Acknowledgements
Not applicable

Author Information
Department of Pain Management, Shandong Provincial Hospital affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, China
References

1. Butterworth JF. Models and mechanisms of local anesthetic cardiac toxicity: a review. Reg Anesth Pain Med. 2010. 35(2): 167-76.

2. Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology. 1979. 51(4): 285-7.

3. Yu CC, Chia-Ti T, Chen PL, Wu CK, Chiu FC, Chiang FT, Chen PS, Chen CL, Lin LY, Juang JM, Ho LT, Lai LP, Yang WS, Lin JL. KCNN2 polymorphisms and cardiac tachyarrhythmias. Medicine. 2016. 95(29): e4312.

4. Clarkson CW, Hondeghem LM. Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole. Anesthesiology. 1985. 62(4): 396.

5. Valenzuela C, Snyders DJ, Bennett PB, Tamargo J, Hondeghem LM. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation. 1995. 92(10): 3014-24.

6. Zapata-Sudo G, Trachez MM, Sudo RT, Nelson TE. Is comparative cardiotoxicity of S(-) and R(+) bupivacaine related to enantiomer-selective inhibition of L-type Ca(2+) channels. Anesthesia & Analgesia. 2001. 92(2): 496-501.

7. Rossner KL, Freese KJ. Bupivacaine inhibition of L-type calcium current in ventricular cardiomyocytes of hamster. Anesthesiology. 1997. 87(4): 926-34.

8. Castle NA. Bupivacaine inhibits the transient outward K+ current but not the inward rectifier in rat ventricular myocytes. Journal of Pharmacology & Experimental Therapeutics. 1990. 255(3): 1038-1046.

9. Courtney KR, Kendig JJ. Bupivacaine is an effective potassium channel blocker in
heart. BBA - Biomembranes. 1988. 939(1): 163-6.

10. Xia XM, Fakler B, Rivard A, Wayman G, Johnson-Pais T, Keen JE, Ishii T, Hirschberg B, Bond CT, Lutsenko S, Maylie J, Adelman JP. Mechanism of calcium gating in small-conductance calcium-activated potassium channels. Nature. 1998. 395(6701): 503-7.

11. Tuteja D, Xu D, Timofeyev V, Lu L, Sharma D, Zhang Z, Xu Y, Nie L, Vázquez AE, Young JN, Glatter KA, Chiamvimonvat N. Differential expression of small-conductance Ca2+-activated K+ channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes. Am J Physiol Heart Circ Physiol. 2005. 289(6): H2714-23.

12. Zhang Q, Timofeyev V, Lu L, Li N, Singapuri A, Long MK, Bond CT, Adelman JP, Chiamvimonvat N. Functional roles of a Ca2+-activated K+ channel in atrioventricular nodes. Circ Res. 2008. 102(4): 465-71.

13. Reher TA, Wang Z1, Hsueh CH, Chang PC, Pan Z, Kumar M, Patel J, Tan J, Shen C, Chen Z, Fishbein MC, Rubart M, Boyden P, Chen PS. Small-Conductance Calcium-Activated Potassium Current in Normal Rabbit Cardiac Purkinje Cells. Journal of the American Heart Association Cardiovascular & Cerebrovascular Disease. 2017. 6(6): e005471.

14. Li N, Timofeyev V, Tuteja D, Xu D, Lu L, Zhang Q, Zhang Z, Singapuri A, Albert TR, Rajagopal AV, Bond CT, Periasamy M, Adelman J, Chiamvimonvat N. Ablation of a Ca2+-activated K+ channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation. J Physiol. 2010. 587(5): 1087-100.

15. Chen KH, Liu H, Sun HY, Jin MW, Xiao GS, Wang Y, Li GR. The Natural Flavone Acacetin Blocks Small Conductance Ca2+-Activated K+ Channels Stably Expressed in HEK 293 Cells. Front Pharmacol. 2017. 8: 716.

16. Benton DC, Monaghan AS, Hosseini R, Bahia PK, Haylett DG, Moss GW. Small conductance Ca2+-activated K+ channels formed by the expression of rat SK1 and
SK2 genes in HEK 293 cells. Journal of Physiology. 2010. 553(1): 13-9.

17. Grunnet M, Jensen BS, Olesen SP, Klaerke DA. Apamin interacts with all subtypes of cloned small-conductance Ca2+-activated K+ channels. Pflügers Archiv. 2001. 441(4): 544-50.

18. Martín P, Enrique N, Palomo ARR, Rebolledo A, Milesi V. Bupivacaine inhibits large conductance, voltage- and Ca2+- activated K+ channels in human umbilical artery smooth muscle cells. Channels. 2012. 6(3): 174-80.

19. Dreixler JC, Jenkins A, Cao YJ, Roizen JD, Houamed KM. Patch-clamp analysis of anesthetic interactions with recombinant SK2 subtype neuronal calcium-activated potassium channels. Anesthesia & Analgesia. 2000. 90(3): 727-32.

20. Stocker M. Ca2+-activated K+ channels: Molecular determinants and function of the SK family. Nat Rev Neurosci. 2004. 5(10): 758-70.

21. Chen MX, Gorman SA, Benson B, Singh K, Hieble JP, Michel MC, Tate SN, Trezise DJ. Small and intermediate conductance Ca(2+)-activated K+ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn Schmiedebergs Arch Pharmacol. 2004. 369(6): 602-15.

22. Bond CT, Herson PT, Hammond R, Stackman R, Maylie J, Adelman JP. Small conductance Ca2+-activated K+ channel knock-out mice reveal the identity of calcium-dependent afterhyperpolarization currents. J Neurosci. 2004. 24(23): 5301-6.

23. Hancock JM, Weatherall KL, Choisy SC, James AF, Hancox JC, Marrion NV. Selective activation of heteromeric SK channels contribute to action potential repolarization in mouse atrial myocytes. Heart Rhythm. 2015. 12(5): 1003-15.

24. Mulroy MF. Systemic toxicity and cardiotoxicity from local anesthetics: Incidence and preventive measures. Regional Anesthesia & Pain Medicine. 2002. 27(6): 556-61.
25. Krabbendam IE, Honrath B, Culmsee C, Dolga AM. Mitochondrial Ca2+-activated K+ channels and their role in cell life and death pathways. Cell Calcium. 2018 : 101-11.

26. Kang SH, Park WS, Kim N, Youm JB, Warda M, Ko JH, Ko EA, Han J. Mitochondrial Ca2+-activated K+ channels more efficiently reduce mitochondrial Ca2+ overload in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2007. 293(1): H307.

27. Honrath B, Matschke L, Meyer T, Magerhans L, Perocchi F, Ganjam GK, Zischka H, Krasel C, Gerding A, Bakker BM, Bünemann M, Strack S, Decher N, Culmsee C, Dolga AM. SK2 channels regulate mitochondrial respiration and mitochondrial Ca2+ uptake. BBA - Bioenergetics. 2017. 1857(5): 761-73.

Figures
Figure 1

SK2 currents recorded from SK2 cell. (A) Superimposed SK2 current traces was recorded from a SK2 cell and a HEK293 cell. (B) SK2 current traces obtained at time points marked with arrow a and b in (C). The protocol shown in the inset was used to activate SK2 current. (C) Time course of SK2 current in a SK2 cell measured at 0 mV. The current could be inhibited by 100 nM apamin completely and the pipette solution contained 1 mM free calcium. SK2 cell:HEK 293 cell transfected with SK2 genes.
Figure 2

Concentration-dependent inhibitory effects of bupivacaine, ropivacaine and lidocaine on SK2 currents. (A) Time course of SK2 currents obtained at 0 mV in the presence or absence of different bupivacaine concentrations and apamin. (B,C and D) Dose-dependent effects of bupivacaine for inhibiting SK2 current (0 mV) was fitted to a Hill equation to obtain IC50 value of bupivacaine, ropivacaine and lidocaine, respectively. The pipette solution contained 1 mM free calcium.
Inhibitory effects of LAS on SK2 currents are reversible (n=7 in each concentration). SK2 currents (0 mV) obtained at baseline, inhibition and washout phases when exposing to 10, 100 and 1000 μM bupivacaine. The intrapipette free calcium concentration was 1 mM. *P < 0.05, compared with baseline value.
Figure 4

Effect of calcium concentration on the inhibitory effect of bupivacaine. (A) SK2 currents obtained at 0 mV in different concentrations of free calcium (n=8). (B) The degree of inhibition of SK2 currents (0 mV) by 100 μM bupivacaine when the pipette solution contained different concentrations of free calcium (n=8). *P < 0.05, between 0.25 mM group and 0.5 mM group, #P < 0.05, between 0.5 mM group and 1 mM group.